GSK and RB desert Pfizer
This article was originally published in OTC Bulletin & The Rose Sheet
GlaxoSmithKline (GSK) and Reckitt Benckiser (RB) have pulled out of the race to acquire Pfizer Consumer Healthcare, with both firms separately confirming that they had ended talks with the US pharmaceuticals giant.
You may also be interested in...
Reckitt Benckiser's long-serving CEO, Rakesh Kapoor, has unexpectedly announced his intention to retire by the end of the year, with the company immediately kicking off the search for his replacement. Kapoor will be remembered for transforming RB's consumer health business, but also for a number of setbacks under his watch which have impacted results.
Shanghai Henlius Biotech has announced that China’s NMPA has accepted the firm’s filing for its HLX14 denosumab biosimilar. Meanwhile, the company has also announced dosing the first patient in a Phase II clinical trial of its novel HLX10 anti-PD-1 monoclonal antibody.
The Global AMR R&D Hub’s newly launched Dynamic Dashboard aims to be “a comprehensive knowledge center for AMR R&D and market reforms,” its head tells Scrip.